Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

被引：0
|
作者：
Wainberg, Zev A.
Bendell, Johanna C.
Lenz, Heinz-Josef
Baron, Ari David
Berlin, Jordan
Bessudo, Alberto
Bruetman, Daniel
Chung, Ki Y.
Park, Haeseong
Patel, Manish R.
Adewoye, Adeboye H.
Liu, JieJane
Patel, Ravindranath
Shah, Manish A.
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] USC, Keck Sch Med, Los Angeles, CA USA
[4] Calif Pacif Med Ctr Res Inst, San Francisco, CA USA
[5] Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN USA
[6] Calif Canc Care Associates Res & Excellence, Encinitas, CA USA
[7] Goshen Ctr Canc Care, Goshen, IN USA
[8] Greenville Hlth Syst Canc Inst, Greenville, SC USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[11] Gilead Sci Inc, Foster City, CA USA
[12] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[13] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Yosuke Horita
    Yasuhide Yamada
    Ken Kato
    Yoshinori Hirashima
    Kouhei Akiyoshi
    Kengo Nagashima
    Takako Nakajima
    Tetsuya Hamaguchi
    Yasuhiro Shimada
    International Journal of Clinical Oncology, 2012, 17 : 604 - 609
  • [22] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Horita, Yosuke
    Yamada, Yasuhide
    Kato, Ken
    Hirashima, Yoshinori
    Akiyoshi, Kouhei
    Nagashima, Kengo
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 604 - 609
  • [23] Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
    Peeters, M.
    Price, T. J.
    Cervantes, A.
    Sobrero, A. F.
    Ducreux, M.
    Hotko, Y.
    Andre, T.
    Chan, E.
    Lordick, F.
    Punt, C. J. A.
    Strickland, A. H.
    Wilson, G.
    Ciuleanu, T. E.
    Roman, L.
    Van Cutsem, E.
    Tian, Y.
    Sidhu, R.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 107 - 116
  • [24] Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer
    Sobrero, Alberto
    Ackland, Stephen
    Clarke, Stephen
    Perez-Carrion, Ramon
    Chiara, Silvia
    Gapski, John
    Mainwaring, Paul
    Langer, Bernd
    Young, Scott
    ONCOLOGY, 2009, 77 (02) : 113 - 119
  • [25] A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation
    Lenz, Heinz-Josef
    Ahn, Daniel H.
    Ridinger, Maya
    Erlander, Mark G.
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [26] Efficacy of ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer
    Katata, Y.
    Nagasaka, T.
    Tanioka, H.
    Nyuya, A.
    Toshima, T.
    Mori, Y.
    Shigeyasu, K.
    Okawaki, M.
    Yamamura, M.
    Tsuruta, A.
    Ueno, T.
    Yamaguchi, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 33 - 33
  • [27] Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
    Sun, Yongkun
    Zhang, Jing
    Wu, Guifu
    Zhong, Xiaomin
    Zhang, Wen
    Liang, Ping
    Li, Baoqi
    Cui, Chengxu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 155 - 155
  • [28] SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Cohn, Allen
    Dakhil, Shaker
    Saleh, Mansoor
    Piperdi, Bilal
    Cline-Burkhardt, Mika
    Tian, Ying
    Go, William Y.
    CLINICAL COLORECTAL CANCER, 2015, 14 (02) : 72 - 80
  • [29] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for metastatic colorectal cancer patients.
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [30] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
12345